UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 162

Sortiert nach

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-07, Vol.52 (1), p.73-84

2020

Volltextzugriff (PDF)

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Inflammatory bowel diseases, 2012-01, Vol.18 (1), p.1-9

2012

Volltextzugriff (PDF)

Stopping Biologics in IBD-What Is the Evidence?

Inflammatory bowel diseases, 2018-03, Vol.24 (4), p.725-731

Louis, Edouard

2018

Volltextzugriff (PDF)

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

The American journal of gastroenterology, 2012-12, Vol.107 (12), p.1770-1776

2012

Volltextzugriff (PDF)

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Inflammatory bowel diseases, 2007-02, Vol.13 (2), p.135-142

2007

Volltextzugriff (PDF)

Long-term summer (AD751-2008) temperature fluctuation in the French Alps based on tree-ring data

Boreas, 2011-04, Vol.40 (2), p.351-366

2011

Volltextzugriff (PDF)

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

The American journal of gastroenterology, 2002-09, Vol.97 (9), p.2357-2363

2002

Volltextzugriff (PDF)

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

Inflammatory bowel diseases, 2011-03, Vol.17 (3), p.858-859

Louis, Edouard

2011

Volltextzugriff (PDF)

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S337-S337

2021

Volltextzugriff (PDF)

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence

United European gastroenterology journal, 2024-06, Vol.12 (5), p.574-584

2024

Volltextzugriff (PDF)

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Volltextzugriff (PDF)

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Inflammatory bowel diseases, 2014-06, Vol.20 (6), p.978-986

2014

Volltextzugriff (PDF)

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Inflammatory bowel diseases, 2024-02, Vol.30 (2), p.240-246

2024

Volltextzugriff (PDF)

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S322-S323

2020

Volltextzugriff (PDF)

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.205-221

2017

Volltextzugriff (PDF)

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S448-S449

2021

Volltextzugriff (PDF)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2017-03, Vol.23 (3), p.333-340

2017

Volltextzugriff (PDF)

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (6), p.779-791

2021

Volltextzugriff (PDF)

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

Alimentary pharmacology & therapeutics, 2020-01, Vol.51 (1), p.129-138

2020

Volltextzugriff (PDF)

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

The American journal of gastroenterology, 2022, Vol.117 (10 Suppl.), p.S704

2022

Volltextzugriff (PDF)

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Inflammatory bowel diseases, 2013-05, Vol.19 (6), p.1112-1122

2013

Volltextzugriff (PDF)

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

Alimentary pharmacology & therapeutics, 2019-12, Vol.50 (11-12), p.1204-1213

2019

Volltextzugriff (PDF)

Development of the Crohn's disease digestive damage score, the Lémann score

Inflammatory bowel diseases, 2011-06, Vol.17 (6), p.1415-1422

2011

Volltextzugriff (PDF)

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e591-e592

2022

Volltextzugriff (PDF)

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e496-e497

2022

Volltextzugriff (PDF)

1 – 25 von 162

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(115)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Stopping Biologics in IBD-What Is the Evidence?

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Long-term summer (AD751-2008) temperature fluctuation in the French Alps based on tree-ring data

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

Development of the Crohn's disease digestive damage score, the Lémann score

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

Aktive Filter

Suchergebnisse filtern